Shankar Musunuri Sells 100,000 Shares of Ocugen, Inc. (NASDAQ:OCGN) Stock

Ocugen, Inc. (NASDAQ:OCGNGet Rating) CEO Shankar Musunuri sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $1.28, for a total transaction of $128,000.00. Following the transaction, the chief executive officer now directly owns 2,227,950 shares of the company’s stock, valued at $2,851,776. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ocugen Stock Performance

OCGN opened at $1.21 on Friday. Ocugen, Inc. has a 12-month low of $1.09 and a 12-month high of $4.53. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $264.85 million, a PE ratio of -3.46 and a beta of 3.97. The firm has a 50 day moving average of $1.39 and a two-hundred day moving average of $1.94.

Ocugen (NASDAQ:OCGNGet Rating) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, analysts anticipate that Ocugen, Inc. will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Ocugen

A number of institutional investors have recently bought and sold shares of OCGN. State Street Corp grew its stake in shares of Ocugen by 108.0% during the 1st quarter. State Street Corp now owns 29,153,704 shares of the company’s stock worth $96,207,000 after purchasing an additional 15,136,085 shares during the period. Bank of America Corp DE grew its stake in shares of Ocugen by 199.0% during the 1st quarter. Bank of America Corp DE now owns 2,789,839 shares of the company’s stock worth $9,207,000 after purchasing an additional 1,856,804 shares during the period. UBS Group AG grew its stake in shares of Ocugen by 158.1% during the 1st quarter. UBS Group AG now owns 2,131,074 shares of the company’s stock worth $7,033,000 after purchasing an additional 1,305,248 shares during the period. Barclays PLC grew its stake in shares of Ocugen by 8,751.7% during the 3rd quarter. Barclays PLC now owns 1,202,242 shares of the company’s stock worth $2,140,000 after purchasing an additional 1,188,660 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Ocugen by 344.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 980,928 shares of the company’s stock worth $3,238,000 after purchasing an additional 760,306 shares during the period. 37.54% of the stock is owned by hedge funds and other institutional investors.

Ocugen Company Profile

(Get Rating)

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.

Read More

Insider Buying and Selling by Quarter for Ocugen (NASDAQ:OCGN)

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.